Posters provide a vital part of your Scientific Sessions 2019 educational experience.

We have made your learning more convenient by integrating the posters throughout the Science & Technology Hall. To narrow your search of over 3,000 posters, we have organized the posters into four poster zones.

Abstract Poster Sessions will occur all three days. Authors are available to discuss their research, at various designated times. Poster Professors are present, making rounds to meet authors for increased interaction and robust discussion.

SCIENCE & TECHNOLOGY HALL HOURS
SATURDAY, NOV. 16: Noon - 6 p.m.
SUNDAY, NOV. 17: 10 a.m.-4:30 p.m.
MONDAY, NOV. 18: 10 a.m.-3 p.m.

Discover even more new research in the Digital Moderated Posters area, located in the HEART Hub.

Are we missing a key target in their thrombotic risk?

In patients with CAD/PAD over 2 years, event rates doubled for major cardiovascular events even with the standard of care*1

<table>
<thead>
<tr>
<th>YEAR 1</th>
<th>YEAR 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAD</td>
<td>PAD</td>
</tr>
<tr>
<td>MI, STROKE, CV DEATH, OR REHOSPITALIZATION</td>
<td>MI, STROKE, CV DEATH, OR REHOSPITALIZATION</td>
</tr>
<tr>
<td>15.2</td>
<td>21.1</td>
</tr>
<tr>
<td>(n=38,602)</td>
<td>(n=7911)</td>
</tr>
</tbody>
</table>

*1 In patients with symptomatic disease, major cardiovascular events defined as death, acute, cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or incident in patients eligible for type [MI, STROKE, CV DEATH, OR REHOSPITALIZATION] in the Coats [2012] and type [MI, STROKE] evaluation. Patient enrolment began in December 2003 and ended in December 2004.

† For secondary prevention of major cardiovascular events with chronic CAD or PAD.

The dynamic interplay of thrombin and platelets plays a crucial role in thrombotic risk

When aspirin isn't enough for your CAD/PAD patients, can an anticoagulant play a role in your treatment strategy?

Visit Booth #1011 to Learn More

CAD = coronary artery disease; CV = cardiovascular; PAD = peripheral artery disease. 

In patients with symptomatic disease, major cardiovascular events defined as death, MI, STROKE, CV DEATH, OR REHOSPITALIZATION in patients eligible for 1-year [n=53,211] and 3-year [n=39,675] evaluations. Patient enrollment began in December 2003 and ended in December 2004.

† For secondary prevention of major cardiovascular events with chronic CAD or PAD.

© Janssen Pharmaceuticals, Inc. 2019          October 2019  cp-114355v1

Visit Booth #1011 to Learn More

CAD = coronary artery disease; CV = cardiovascular; PAD = peripheral artery disease.

